Life sciences

Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Life sciences, Articles, Bioethics, Emerging technologies, Genetic engineering, Gene delivery, Gene therapy, Molecular biology, Therapy

CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that upon completion of a number of preclinical and safety studies, it had executed an exclusive license agreement for an investigational gene therapy candidate, calpain 3 (CAPN-3), to treat Limb-girdle muscular dystrophy type 2A (LGMD2A), developed by the Abigail Wexner Research Institute at Nationwide Children’s Hospital (Nationwide Children’s).

Key Points: 
  • Treatment plans for LGMD2A are currently limited to physical therapy, assistive devices and surgery for complications.
  • Were excited about the opportunity to transform patient care for this significantly life-limiting disease by advancing the CAPN-3 program following extensive pre-clinical work by the team at Nationwide Childrens.
  • Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing.
  • Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Health care, Biotechnology, Health sciences, Immunology, Antineoplastic drugs, Bristol-Myers Squibb, Ipilimumab, Antibody-drug conjugate, AbbVie, Biopharmaceutical

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced the publication of three articles in peer-reviewed journals on pacmilimab (CX-072), the Company’s wholly-owned conditionally activated antibody directed against PD-L1 currently being developed in combination with praluzatamab ravtansine (CX-2009) for the treatment of triple-negative breast cancer (TNBC).

Key Points: 
  • Pacmilimab+ipilimumab was administered intravenously every 3 weeks for four cycles, followed by pacmilimab administered every 2 weeks as monotherapy.
  • We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody technology platform, for the treatment of cancer.
  • Probody therapeutics are conditionally activated biologics designed to remain inactive until they are activated by proteases in the tumor microenvironment.
  • First-in-class product candidates against previously undruggable targets include a CD166-targeting conditionally activated antibody-drug conjugate wholly owned by CytomX (praluzatamab ravtansine, CX-2009) and a CD71-targeting conditionally activated antibody-drug conjugate partnered with AbbVie (CX-2029).

IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors

Retrieved on: 
Wednesday, August 4, 2021
Articles, Life sciences, Biotechnology, Luba people, Fairbairn, Board of directors, Biopharmaceutical

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, announces the appointments of Emily Fairbairn and Luba Greenwood as new members of its Board of Directors.

Key Points: 
  • NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, announces the appointments of Emily Fairbairn and Luba Greenwood as new members of its Board of Directors.
  • Emily and Luba have vast experience as entrepreneurs, executives, board members and investors of companies across multiple therapeutic areas in the biopharmaceutical industry, said Alan S. Roemer, Chairman of IN8bios Board of Directors.
  • Ms. Fairbairn is a highly experienced executive and seasoned investor with decades of experience in financial leadership positions.
  • Ms. Fairbairn will be serving on the nomination and corporate governance committee, while Ms. Greenwood will be serving on the audit and compensation committees.

ADMA Biologics to Report Second Quarter 2021 Financial Results on August 11, 2021

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Anatomy, Biotechnology, Blood, Transfusion medicine, Biopharmaceutical, Pharmaceutical industry, Adma, Boca Raton, Florida, Blood plasma

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 after the U.S. financial markets close.

Key Points: 
  • RAMSEY, N.J. and BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 after the U.S. financial markets close.
  • ADMAs management team will host a live conference call and audio webcast on that date at 4:30 p.m.
  • ET to discuss its financial results and other Company updates.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.

Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Health sciences, Articles, Biotechnology, Facioscapulohumeral muscular dystrophy, Muscular dystrophy, Losmapimod, Biopharmaceutical

Following the live webcast, an archived replay will also be available.

Key Points: 
  • Following the live webcast, an archived replay will also be available.
  • Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need.
  • Fulcrums proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression.
  • The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral dystrophy (FSHD).

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Health, Food and Drug Administration, Life sciences, Pharmaceuticals policy, Drug discovery, Biotechnology law, Orphan drug, Orphan Drug Act, Clinical trial, Food and Drug Administration Safety and Innovation Act, Breakthrough therapy

The FDA evaluated the research data licensed from KU in the ODD application that ultimately served as the foundation to allow the FDA to grant the designation.

Key Points: 
  • The FDA evaluated the research data licensed from KU in the ODD application that ultimately served as the foundation to allow the FDA to grant the designation.
  • The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor.
  • The FDA grants orphan status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.
  • PharmaTher is currently initiating an FDA approved phase 2 clinical study with ketamine to treat Parkinsons disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics.

ProMIS Neurosciences Issues Chairman’s Memorandum

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Biology, Amyloidosis, Life sciences, Alzheimer's disease, Monoclonal antibodies, Aducanumab, Biogen, Amyloid beta, Amyloid, PROMIS, Neurodegeneration

TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairmans memorandum, commenting on highlights of the recent 2021 Alzheimers Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting.

Key Points: 
  • TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairmans memorandum, commenting on highlights of the recent 2021 Alzheimers Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting.
  • We are in a new era in the fight against Alzheimers, ALS, and other neurodegenerative diseases, stated Eugene Williams, Executive Chairman of ProMIS Neurosciences.
  • The Chairmans memorandum highlights the recent FDA accelerated approval of Biogens Aduhelm (aducanumab) which now provides a regulatory path to approval in AD, opening the door to development of next generation therapies selectively targeting the pathogenic forms of amyloid-beta.
  • ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Biotechnology, Articles, Specialty drugs, Kura, Biopharmaceutical, Precision medicine, Oncology

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual Conference.

Key Points: 
  • SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual Conference.
  • Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a panel titled Bullseye - Targeted Oncology Part 2 at 10:20 a.m.
  • Kura Oncologyis a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • For additional information about Kura, please visit the Companys website at www.kuraoncology.com .

Day One Biopharmaceuticals to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Health sciences, Biotechnology, Drugs, Targeted therapy, Treatment of cancer, Oncology, Cancer, Biopharmaceutical, Cancer research

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers.

Key Points: 
  • Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers.
  • Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution.
  • We aim to re-envision cancer drug development and redefine whats possible for all people living with cancerregardless of agestarting from Day One.
  • Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments.

Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Retrieved on: 
Wednesday, August 4, 2021
Amicus Therapeutics, Gene therapy, Folding, Life sciences, Health care, Companies

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 9:00 a.m. E.T.

Key Points: 
  • PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 9:00 a.m. E.T.
  • Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.
  • With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.
  • For more information please visit the companys website at www.amicusrx.com , and follow us on Twitter and LinkedIn .